Robert M. Knabb

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

Samuel Z. Goldhaber, Alain Leizorovicz, Ajay K. Kakkar et al. · New England Journal of Medicine · 2011 · 542 citations · Full text

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Stephanie C. Koch et al. · Journal of Medicinal Chemistry · 2007 · 391 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Primary Aniline +15

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

Pancras C. Wong, Earl J. Crain, Bailong Xin et al. · Journal of Thrombosis and Haemostasis · 2008 · 299 citations · Full text

Thrombopoiesis, Thrombosis, Medicinal Chemistry +8

The selective inhibition of thrombin by peptides of boroarginine.

Charles A. Kettner, Lawrence J. Mersinger, Robert M. Knabb · Journal of Biological Chemistry · 1990 · 253 citations · Full text

Peptide Engineering, Peptide Science, Pharmacotherapy +20

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han et al. · Journal of Medicinal Chemistry · 2004 · 188 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +17